Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

The FDA Grants Breakthrough Therapy Designation To Lexeo Therapeutics' LX2006 Based On Clinical Evidence Generated On Both Cardiac And Neurologic Measures Of Friedreich Ataxia

Author: Benzinga Newsdesk | July 07, 2025 07:06am

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, intended to enable earlier patient access to therapies with expedited clinical development timelines.

Posted In: LXEO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist